Short answer: there is no official taper schedule for semaglutide or tirzepatide — but the early real-world data favors a slow, planned step-down over an abrupt stop, and the single highest-value move is to make the exit a plan you build with your prescriber, not a decision you make alone the week your prescription runs out.

Most people do not stay on these medications for life: more than half stop within the first year, often for cost, coverage, or side-effect reasons rather than by choice (real-world data via Medscape). So the exit is not an edge case — it is the normal course of a GLP-1 prescription, and it deserves the same deliberateness as the start. The numbers behind everything below are collected, with sources, in our statistics page.

Why the exit needs a plan at all

The trials that followed people after an abrupt stop are consistent: roughly two-thirds of the lost weight returned within a year of stopping semaglutide (STEP 1 extension), and people switched from tirzepatide to placebo regained 14% of body weight in 52 weeks while those who stayed on lost more (SURMOUNT-4). A narrative review of the randomized studies reads the same way across liraglutide, semaglutide, and tirzepatide: interruption without a plan means most of the weight comes back.

Two things make that worse than it sounds, and both are covered in our after-GLP-1 guide: the weight lost was partly lean mass, and weight regained without resistance training is predominantly fat — so “back to the same number” can be a worse body composition than where you started.

What the tapering evidence actually shows — and its limits

The most encouraging data so far comes from a Danish digital weight-loss clinic that stepped patients down slowly instead of stopping them cold: tapering over a median of nine weeks, patients kept losing a little weight during the step-down (about 2.1%), and the 85 patients with follow-up data held a stable weight 26 weeks after the last dose (reported at Medscape). Notably, the same program used personalized doses well below the standard escalation schedule and saw comparable results.

Now the honest limits, because they matter:

  • This is retrospective, real-world data from one clinic’s program — not a randomized trial. The patients also received structured lifestyle coaching throughout, so the taper and the coaching cannot be separated.
  • The randomized answer does not exist yet. Two registered trials are built exactly on this question — a dose-tapering regimen for weight-loss maintenance (NCT07783854) and a comparison of options after stopping semaglutide or tirzepatide (NCT06605703). Until they report, tapering is a reasonable strategy with promising early data, not a proven protocol.
  • In practice, many clinicians step down through the same doses used on the way up, at similar intervals. That is extrapolation from the escalation schedule, not a tested regimen — which is precisely why this is a conversation with your prescriber, not a plan to copy from the internet.

The maintenance-dose option

Stopping entirely is not the only exit. SURMOUNT-4’s continuation arm is, read plainly, a maintenance result: people who stayed on tirzepatide after nine months kept losing rather than regaining. Some prescribers extend that logic to a lower ongoing dose — enough to hold the result at less cost and fewer side effects — and the Danish data above, where personalized lower doses performed comparably to standard ones, points the same direction. Whether that fits your case (and your insurance) is a prescriber decision, but it belongs on the table before “stop” is read as the only option after “continue at full dose.”

The clinician conversation: what to actually ask

Bring these questions to the appointment where you discuss stopping:

  1. Do I taper, and on what schedule? If the answer is an abrupt stop, ask what that recommendation is based on — and mention you have read that stepped reductions are being studied.
  2. Is a lower maintenance dose an option for me — medically, and under my coverage?
  3. What do we watch, and when do we check it? Weight is the crude metric; appetite rebound, waist measurement, and strength are the ones that describe what the regain is made of.
  4. At what point would we consider resuming, and would restarting mean re-escalating from the lowest dose?
  5. What is my plan for the two levers that are mine? Appetite comes back before habits change — walking in with a written protein target and a training schedule makes the whole plan more credible, including to yourself.

The part no prescription covers

Whatever exit you and your clinician choose, the regain data has one consistent exception channel: people who hold onto muscle regain less, and what they regain lands better. That part is not in the pen or the taper — it is 1.2–1.6 g of protein per kg of body weight per day (our protein guide turns that into meals) and two to three strength sessions a week (our starter plan is built for exactly this moment). Start both before the last dose, not after: the taper weeks are the cheapest window you will ever get to build the habits that have to carry the result afterward.

This article is educational and is not medical advice. Decisions about starting, changing, or stopping a prescription medication belong with you and your prescriber.